Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25.

Scally SW, McLeod B, Bosch A, Miura K, Liang Q, Carroll S, Reponen S, Nguyen N, Giladi E, Rämisch S, Yusibov V, Bradley A, Lemiale F, Schief WR, Emerling D, Kellam P, King CR, Julien JP.

Nat Commun. 2017 Nov 16;8(1):1568. doi: 10.1038/s41467-017-01924-3.


Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis.

Chaudhury S, Regules JA, Darko CA, Dutta S, Wallqvist A, Waters NC, Jongert E, Lemiale F, Bergmann-Leitner ES.

Sci Rep. 2017 Aug 11;7(1):7998. doi: 10.1038/s41598-017-08526-5.


A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum.

Radin K, Clement F, Jongert E, Sterckx YG, Ockenhouse C, Regules J, Lemiale F, Leroux-Roels G.

Malar J. 2016 Nov 8;15(1):543.


The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity.

Chaudhury S, Ockenhouse CF, Regules JA, Dutta S, Wallqvist A, Jongert E, Waters NC, Lemiale F, Bergmann-Leitner E.

Malar J. 2016 May 31;15:301. doi: 10.1186/s12936-016-1348-9.


An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization.

Lemiale F, Asefa B, Ye D, Chen C, Korokhov N, Humeau L.

Vaccine. 2010 Feb 23;28(8):1952-61. doi: 10.1016/j.vaccine.2009.10.089.


Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.

Asefa B, Korokhov N, Lemiale F.

Vaccine. 2010 Apr 30;28(20):3617-24. doi: 10.1016/j.vaccine.2009.12.047. Epub 2010 Jan 4.


Lentiviral vectors for HIV disease prevention and treatment.

Lemiale F, Korokhov N.

Vaccine. 2009 May 26;27(25-26):3443-9. doi: 10.1016/j.vaccine.2009.01.055. Epub 2009 Feb 6. Review.


Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41.

Lemiale F, Haddada H, Nabel GJ, Brough DE, King CR, Gall JG.

Vaccine. 2007 Mar 1;25(11):2074-84. Epub 2006 Nov 28.


Gene transfer in humans using a conditionally replicating lentiviral vector.

Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, Binder GK, Slepushkin V, Lemiale F, Mascola JR, Bushman FD, Dropulic B, June CH.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17372-7. Epub 2006 Nov 7.


Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system.

Lemiale F, Kong WP, Akyürek LM, Ling X, Huang Y, Chakrabarti BK, Eckhaus M, Nabel GJ.

J Virol. 2003 Sep;77(18):10078-87.


The transmembrane protein of HIV-1 primary isolates modulates cell surface expression of their envelope glycoproteins.

Lebigot S, Roingeard P, Thibault G, Lemiale F, Verrier B, Barin F, Brand D.

Virology. 2001 Nov 10;290(1):136-42.


Immunogenicity of recombinant envelope glycoproteins derived from T-cell line-adapted isolates or primary HIV isolates: a comparative study using multivalent vaccine approaches.

Lemiale F, Brand D, Lebigot S, Verrier B, Buzelay L, Brunet S, Barin F.

J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):413-22.


Identification of the glycoprotein 41(TM) cytoplasmic tail domains of human immunodeficiency virus type 1 that interact with Pr55Gag particles.

Hourioux C, Brand D, Sizaret PY, Lemiale F, Lebigot S, Barin F, Roingeard P.

AIDS Res Hum Retroviruses. 2000 Aug 10;16(12):1141-7.


Antigenic properties of recombinant envelope glycoproteins derived from T-cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity.

Brand D, Lemiale F, Thibault G, Verrier B, Lebigot S, Roingeard P, Buzelay L, Brunet S, Barin F.

Virology. 2000 Jun 5;271(2):350-62.


Supplemental Content

Loading ...
Support Center